198 related articles for article (PubMed ID: 23351188)
1. Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors.
Zhu Y; Yang J; Jiao S; Ji T
World J Surg Oncol; 2013 Jan; 11():19. PubMed ID: 23351188
[TBL] [Abstract][Full Text] [Related]
2. The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study.
Chen XF; Wang R; Yin YM; Røe OD; Li J; Zhu LJ; Guo RH; Wu T; Shu YQ
Biomed Pharmacother; 2012 Jun; 66(4):279-84. PubMed ID: 22397758
[TBL] [Abstract][Full Text] [Related]
3. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
Wang DS; Wang ZQ; Chen G; Peng JW; Wang W; Deng YH; Wang FH; Zhang JW; Liang HL; Feng F; Xie CB; Ren C; Jin Y; Shi SM; Fan WH; Lu ZH; Ding PR; Wang F; Xu RH; Li YH
Cancer Med; 2020 Jan; 9(1):151-159. PubMed ID: 31724334
[TBL] [Abstract][Full Text] [Related]
4. Ganglioside-monosialic acid (GM1) for prevention of chemotherapy-induced peripheral neuropathy: a meta-analysis with trial sequential analysis.
Wu S; Bai X; Guo C; Huang Z; Ouyang H; Huang J; Zeng W
BMC Cancer; 2021 Nov; 21(1):1173. PubMed ID: 34727879
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Exercise Rehabilitation Program in Relieving Oxaliplatin Induced Peripheral Neurotoxicity.
Gui Q; Li D; Zhuge Y; Xu C
Asian Pac J Cancer Prev; 2021 Mar; 22(3):705-709. PubMed ID: 33773532
[TBL] [Abstract][Full Text] [Related]
6. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.
Argyriou AA; Velasco R; Briani C; Cavaletti G; Bruna J; Alberti P; Cacciavillani M; Lonardi S; Santos C; Cortinovis D; Cazzaniga M; Kalofonos HP
Ann Oncol; 2012 Dec; 23(12):3116-3122. PubMed ID: 22865779
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
8. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.
Argyriou AA; Cavaletti G; Antonacopoulou A; Genazzani AA; Briani C; Bruna J; Terrazzino S; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Psaromyalou A; Angelopoulou A; Kalofonos HP
Cancer; 2013 Oct; 119(19):3570-7. PubMed ID: 23821303
[TBL] [Abstract][Full Text] [Related]
9. Effects of compound porcine cerebroside and ganglioside on neurotoxicity caused by oxaliplatin chemotherapy: preliminary results.
Zhang YL; Wei LY; Yao HW; Jin L; Wang J; Zhang J; Zhao XM; Cai J; Bai ZG; Deng W
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5441-5448. PubMed ID: 31298397
[TBL] [Abstract][Full Text] [Related]
10. Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer.
Teng C; Reuter SE; Blinman PL; Dhillon HM; Galettis P; Proschogo N; McLachlan AJ; Vardy JL
Cancer Chemother Pharmacol; 2020 Oct; 86(4):547-558. PubMed ID: 32949265
[TBL] [Abstract][Full Text] [Related]
11. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
Kono T; Hata T; Morita S; Munemoto Y; Matsui T; Kojima H; Takemoto H; Fukunaga M; Nagata N; Shimada M; Sakamoto J; Mishima H
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1283-90. PubMed ID: 24121454
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
[TBL] [Abstract][Full Text] [Related]
13. Effects of analgecine on oxaliplatin-induced neurotoxicity in patients with gastrointestinal cancer.
Liu MY; Huang XE
Asian Pac J Cancer Prev; 2015; 16(10):4465-8. PubMed ID: 26028115
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran.
Shahriari-Ahmadi A; Fahimi A; Payandeh M; Sadeghi M
Asian Pac J Cancer Prev; 2015; 16(17):7603-6. PubMed ID: 26625769
[TBL] [Abstract][Full Text] [Related]
15. [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
Muto O; Ando H; Ono T; Itagaki H; Kobayashi Y; Onuki M; Akashi T; Tanaka Y; Hanaoka T
Gan To Kagaku Ryoho; 2007 Apr; 34(4):579-81. PubMed ID: 17431344
[TBL] [Abstract][Full Text] [Related]
16. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Oncologist; 2011; 16(5):708-16. PubMed ID: 21478275
[TBL] [Abstract][Full Text] [Related]
17. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients.
Knijn N; Tol J; Koopman M; Werter MJ; Imholz AL; Valster FA; Mol L; Vincent AD; Teerenstra S; Punt CJ
Eur J Cancer; 2011 Feb; 47(3):369-74. PubMed ID: 21067912
[TBL] [Abstract][Full Text] [Related]
18. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy.
Saif MW; Syrigos K; Kaley K; Isufi I
Anticancer Res; 2010 Jul; 30(7):2927-33. PubMed ID: 20683034
[TBL] [Abstract][Full Text] [Related]
19. Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy.
Chay WY; Tan SH; Lo YL; Ong SY; Ng HC; Gao F; Koo WH; Choo SP
Asia Pac J Clin Oncol; 2010 Dec; 6(4):270-7. PubMed ID: 21114776
[TBL] [Abstract][Full Text] [Related]
20. L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways.
Yehia R; Saleh S; El Abhar H; Saad AS; Schaalan M
Toxicol Appl Pharmacol; 2019 Feb; 365():41-50. PubMed ID: 30592963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
